Published in J Neurochem on May 26, 2010
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci (2012) 1.63
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
Prospects of statins in Parkinson disease. Neuroscientist (2011) 1.07
The Role of immune and inflammatory mechanisms in ALS. Curr Mol Med (2011) 1.05
Methamphetamine-associated psychosis. J Neuroimmune Pharmacol (2011) 1.05
Parkinson's disease and systemic inflammation. Parkinsons Dis (2011) 0.96
Functional proteomic analysis for regulatory T cell surveillance of the HIV-1-infected macrophage. J Proteome Res (2010) 0.95
Bone marrow-derived microglia infiltrate into the paraventricular nucleus of chronic psychological stress-loaded mice. PLoS One (2013) 0.87
Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease. PLoS One (2015) 0.86
Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother (2011) 0.84
Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice. J Neurosci (2015) 0.80
Taking the Perspective that a Depressive State Reflects Inflammation: Implications for the Use of Antidepressants. Front Psychol (2012) 0.76
Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. Neurotherapeutics (2016) 0.75
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
IL-17 and Th17 Cells. Annu Rev Immunol (2009) 23.02
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
The many faces of macrophage activation. J Leukoc Biol (2003) 8.95
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med (2001) 7.85
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol (2007) 6.67
Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med (2007) 6.61
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007) 5.46
IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A (2003) 5.09
Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol (2006) 4.87
Immune function of microglia. Glia (2001) 4.59
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 4.21
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med (2000) 4.18
Risk of Alzheimer's disease and duration of NSAID use. Neurology (1997) 4.06
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood (2008) 3.95
Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci (2005) 3.93
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 3.89
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol (2005) 3.58
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci (2001) 3.55
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A (2008) 3.40
T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol (2003) 3.38
The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev (2008) 3.32
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron (2005) 3.20
CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology (2006) 3.01
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest (2006) 2.86
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ (2003) 2.74
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology (2004) 2.63
The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology (2009) 2.62
Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem (1995) 2.60
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis (2005) 2.59
NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging (2006) 2.55
Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci (2003) 2.52
The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol (2009) 2.39
Molecular transductional mechanisms by which IFN gamma and other signals regulate macrophage development. Immunol Rev (1987) 2.37
Functional recovery in parkinsonian monkeys treated with GDNF. Nature (1996) 2.35
The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci (2003) 2.35
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology (2009) 2.32
Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol (2000) 2.30
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes (2002) 2.24
Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord (2002) 2.23
Why do COX-2 inhibitors increase risk of cardiovascular events? Lancet (2002) 2.21
Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol (2008) 2.18
Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci (1999) 2.13
Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology (2002) 2.12
Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol (2001) 2.11
M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol (2009) 2.06
Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry (2008) 2.06
Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci (2000) 2.03
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology (1995) 1.92
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology (2004) 1.92
Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol (2005) 1.86
Minocycline and neurodegenerative diseases. Behav Brain Res (2008) 1.82
Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2002) 1.81
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol (2007) 1.80
The age-related attenuation in long-term potentiation is associated with microglial activation. J Neurochem (2006) 1.76
A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol (2008) 1.74
[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology (2001) 1.65
Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci (2003) 1.58
Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res (2001) 1.57
Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol (2010) 1.57
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem (2006) 1.49
1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-beta. J Immunol (2008) 1.49
Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry (2000) 1.49
Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet (2001) 1.43
Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci (1995) 1.42
Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia (2006) 1.41
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol (2010) 1.39
Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis (2008) 1.39
Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38
Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology (2010) 1.38
Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem (2007) 1.35
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res (2009) 1.34
Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg (2007) 1.34
IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol (2005) 1.34
Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation (2006) 1.32
Microglia in neurodegeneration: molecular aspects. Microsc Res Tech (2001) 1.32
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse (2001) 1.31
Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (2001) 1.30
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci (2004) 1.30
Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther (1985) 1.29
T regulatory cells and their counterparts: masters of immune regulation. Clin Exp Allergy (2009) 1.28
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement (2009) 1.28
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol (2006) 2.24
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol (2007) 1.84
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol (2007) 1.80
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol (2012) 1.78
HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab (2006) 1.72
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J Leukoc Biol (2003) 1.62
A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem (2006) 1.61
STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood (2007) 1.60
Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol (2010) 1.57
NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) (2009) 1.55
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood (2005) 1.54
HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read (2002) 1.54
Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) (2011) 1.52
Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis (2007) 1.52
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron (2009) 1.48
HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr (2002) 1.46
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood (2010) 1.44
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J Immunol (2012) 1.42
Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology (2006) 1.41
HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia (2006) 1.40
A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem (2007) 1.38
Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol (2006) 1.37
Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem (2007) 1.35
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res (2007) 1.35
Cell-mediated drug delivery. Expert Opin Drug Deliv (2011) 1.33
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis (2010) 1.32
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology (2007) 1.30
Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci (2003) 1.28
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol (2009) 1.27
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci (2009) 1.27
CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol (2010) 1.27
CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J (2010) 1.25
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis (2012) 1.23
Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol (2002) 1.23
Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci (2011) 1.22
Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia (2003) 1.22
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One (2009) 1.21
Prion interference is due to a reduction in strain-specific PrPSc levels. J Virol (2006) 1.21
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine (2013) 1.21
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother (2013) 1.17
CSF proteomic fingerprints for HIV-associated cognitive impairment. J Neuroimmunol (2007) 1.16
Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci (2005) 1.16
Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J Neurochem (2007) 1.15
Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol (2008) 1.15
Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J Immunol (2009) 1.14
Neurodegenerative disorders and nanoformulated drug development. Nanomedicine (Lond) (2009) 1.14
Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. J Proteome Res (2009) 1.13
Cytoskeletal protein transformation in HIV-1-infected macrophage giant cells. J Immunol (2007) 1.13
Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One (2012) 1.13
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) (2010) 1.12
Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Glia (2005) 1.12